November 19, 2015
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Suzanne Hayes |
| Scot Foley |
| Re: | OncoGenex Pharmaceuticals, Inc. |
| Registration Statement on Form S-3 |
| Filed October 29, 2015 |
| File No. 033-207670 |
Ladies and Gentlemen:
On behalf of OncoGenex Pharmaceuticals, Inc. (the “Company”), we are submitting this letter and the following information in response to a letter, dated November 5, 2015, from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-3 filed with the Commission on October 29, 2015.
We have incorporated the Staff’s comment into this response letter in bold italics and our response is set forth below.
General
| 1. | We note that you have submitted an application for confidential treatment relating to an exhibit you filed with your quarterly report on Form 10-Q for the quarterly period ended June 30, 2015. Please be advised that we will not be in a position to grant effectiveness to your registration statement until such time as this application has completed processing or is withdrawn. |
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the confidential treatment order (File No. 033-80623– CF#32888) relating to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2015 was issued on November 19, 2015.
* * *
U.S. Securities and Exchange Commission
November 19, 2015
Page 2
Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (206) 389-4559 or, in his absence, Amanda Rose at (206) 389-4553.
| Sincerely,
FENWICK & WEST LLP |
| /s/ James D. Evans |
| James D. Evans |
| cc: | John Bencich, OncoGenex Pharmaceuticals, Inc. |
| Alan Smith, Esq., Fenwick & West LLP |
| Amanda Rose, Esq., Fenwick & West LLP |